Safety, tolerability, and pharmacokinetics of fluoropezil ( DC20 ), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13490 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Hongjie Qian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Acetylcholinesterase, Alzheimer Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The present study evaluated the safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor under development for the treatment of Alzheimer's disease (AD) in otherwise healthy young and elderly Chinese subjects. The study of young subjects included the multiple ascending dose (MAD) arm (2 and 6 mg, N = 24) and the food effect arm (4 mg, N = 12) and was followed by the study of elderly subjects who were given (2 and 4 mg, N = 11). The noncompartmental analysis method was used to determine the pharmacokinetic parameters. The pharmacokinetics of fed versus fasted dose administration in the same subjects was assessed by 90% confidence interval. In the MAD arm, the accumulation ratios of DC20 in vivo were 2.29 and 2.15, respectively. In the food effect arm, compared with fasting administration, an area under the concentration‐time curve from zero to t after a standard and high‐fat diet orally administered slightly increased by about 19% and 29%, and the time to maximum concentration ( T max ) was delayed by around 1 h. For elderly study subjects, T max was 1.5 and 1.25 h, and terminal half‐life ( t 1/2 ) was 77.1 and 74.2 h, respectively. There were no serious adverse events (AEs), whereas gastrointestinal reactions were the most common AEs associated with the study drug. We predicted the safety risks of DC20 in the clinical treatment of AD, which were well‐tolerated by the healthy young and elderly subjects. The elimination of DC20 from the body was slower in elderly subjects than in young subjects. This study was approved by the Center for Drug Evaluation, National Medical Products Administration (CTR20181428, CTR20190664, CTR20191878, and CTR20192724).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- Jiangsu Kanion Pharmaceutical Co., Ltd, Lianyungang, China.
- Shanghai Kerlin Biomedical Technology Co., Ltd, Shanghai, China.
ORCID-Profile: Chengyin Yu, Yun Liu
Zitieren
APA
Qian, H., Yu, C., Zhu, H., Ding, Q., Cai, Y., Jing, J., Xu, X., Guo, R., Zhang, H., Liu, H., Chen, X., & Liu, Y. (2023). Safety, tolerability, and pharmacokinetics of fluoropezil ( DC20 ), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects. Clinical and Translational Science. https://doi.org/10.1111/cts.13490
Vancouver
Qian H, Yu C, Zhu H, Ding Q, Cai Y, Jing J, et al. Safety, tolerability, and pharmacokinetics of fluoropezil ( DC20 ), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects. Clinical and Translational Science. 2023. doi:10.1111/cts.13490
BibTeX
@article{Qian2023,
author = {Qian, Hongjie and Yu, Chengyin and Zhu, Huijuan and Ding, Qichen and Cai, Yuting and Jing, Jiao and Xu, Xin and Guo, Runcong and Zhang, Haiyan and Liu, Hong and Chen, Xiaoyan and Liu, Yun},
title = {Safety, tolerability, and pharmacokinetics of fluoropezil ( DC20 ), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13490}
}
EUVIMED